Trimeris Merger Litigation (Nasdaq: TRMS)
Law Office of Brodsky & Smith, LLC Announces Investigation on Behalf of Shareholders of Trimeris, Inc.
BALA CYNWYD – (BUSINES WIRE) Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Trimeris, Inc. (“Trimeris” or the “Company”) (Nasdaq: TRMS – News) relating to the proposed acquisition by Arigene Co., (“Arigene”). Arigene has agreed to acquire Trimeris in an all-cash deal valued at approximately $81 million.
Under the proposed agreement, Trimeris shareholders will receive $3.60 for every share of Trimeris common stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law related to the Trimeris board’s approval of the proposed merger. The transaction appears to be unfair, because of the price being paid, various deal protections and the Company granted Arigene a top-up option that may allow Arigene to purchase additional shares.
If you own shares of Trimeris and wish to discuss the legal ramifications of the proposed acquisition by Arigene, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at clients@brodsky-smith.com, or by calling toll free 877-LEGAL-90.
To Join the Trimeris Litigation
-
Fill out this form
View Complaint
The complaint is unavailable at this time
Join Other Cases
Frequently Asked Questions